Cargando…

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California

BACKGROUND: Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better understanding of the relationships between tertiary and communi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salgia, Nicholas J., Chehrazi‐Raffle, Alexander, Hsu, JoAnn, Zengin, Zeynep, Salgia, Sabrina, Chawla, Neal S., Meza, Luis, Malhotra, Jasnoor, Dizman, Nazli, Muddasani, Ramya, Ruel, Nora, Cianfrocca, Mary, Gong, Jun, Anand, Sidharth, Chiu, Victor, Yeh, James, Pal, Sumanta K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366095/ https://www.ncbi.nlm.nih.gov/pubmed/34331372 http://dx.doi.org/10.1002/cam4.4119

Ejemplares similares

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
por: Dizman, Nazli, et al.
Publicado: (2022)

Renal Cell Carcinoma With Urinary Bladder Metastasis: A Case Report With Metachronous Genomic Analyses
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2023)

1564MO Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients (pts) with advanced genitourinary (GU) cancers
por: Salgia, S.K., et al.
Publicado: (2021)

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
por: Govindarajan, Ameish, et al.
Publicado: (2023)

Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
por: Gong, Jun, et al.
Publicado: (2018)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic
por: Salgia, Sabrina, et al.
Publicado: (2021)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
por: Gong, Jun, et al.
Publicado: (2019)

An Update on the Treatment of Papillary Renal Cell Carcinoma
por: Chawla, Neal S., et al.
Publicado: (2023)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Being present: oncologists' role in promoting advanced cancer patients' illness understanding
por: Cohen, Simon M., et al.
Publicado: (2018)

Surveillance of the current situation regarding influenza vaccination according to medical oncologists in Japan
por: Maeda, Toshiki, et al.
Publicado: (2020)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities
por: Castro, Daniela V., et al.
Publicado: (2022)

Knowledge and use of prognostic scales by oncologists and palliative care physicians in adult patients with advanced cancer: A national survey (ONCOPRONO study)
por: Dantigny, Raphaëlle, et al.
Publicado: (2021)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists
por: Mileham, Kathryn F., et al.
Publicado: (2021)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Systemic therapy and COVID19: Immunotherapy and chemotherapy
por: Gulati, Shuchi, et al.
Publicado: (2021)

Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
por: Salgia, Meghan, et al.
Publicado: (2017)

COVID-19 Vaccine Perceptions Survey for Real-Time Vaccine Outreach in Marin County, California
por: Soriano, Jasmine, et al.
Publicado: (2023)

Fatality and Injury Severity of Older Adult Motor Vehicle Collisions in Orange County, California, 1998–2007
por: Lotfipour, Shahram, et al.
Publicado: (2013)

California ACEP Firearm Injury Prevention Policy
por: Fernandez, Jorge, et al.
Publicado: (2021)

Value-based genomics
por: Gong, Jun, et al.
Publicado: (2018)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Tobacco smoking, polymorphisms in carcinogen metabolism enzyme genes, and risk of localized and advanced prostate cancer: results from the California Collaborative Prostate Cancer Study
por: Shahabi, Ahva, et al.
Publicado: (2014)

Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
por: Mishra, Sanjeeb K, et al.
Publicado: (2021)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v8ofior72edhosfbciasehbod0